Halozyme Therapeutics in (halo 1 08/15/28)
13F holders, Q2 2024 (June 30)10holders +1
2new positions
1sold out
$1.08avg. 13F price*
At the end of Q2 2024, 10 institutions reported holding Halozyme Therapeutics in (halo 1 08/15/28) in their 13F filings, up 1 from Q1 2024. 2 opened new positions and 1 sold out. The largest holders were Absolute Investment Advisers, LLC ($12.2M), Ofi Invest Asset Management ($5.1M) and New York State Common Retirement Fund ($4.3M).
- Company
- Halozyme Therapeutics in (halo 1 08/15/28)
- CUSIP
- 40637HAF6
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $29K |
| Exits | 1 | $1.3M |
All 13F filers, Q1 2024 → Q2 2024: 104,000 shares bought and 2,460,900 shares sold, net −2,356,900 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Absolute Investment Advisers, LLC | 1.81% | No change | 11,000,000 | $12.2M |
| Ofi Invest Asset Management | 0.14% | Reduce -0.1% | 4,900,000 | $5.1M |
| New York State Common Retirement Fund | 0.01% | Reduce -21.9% | 3,899,000 | $4.3M |
| Sonora Investment Management Group, LLC | 0.18% | No change | 2,335,000 | $2.3M |
| Bank of New York Mellon Corp | 0.00% | No change | 600,000 | $667K |
| Sei Investments Co. | 0.00% | No change | 322,000 | $358K |
| Oppenheimer Asset Management Inc. | 0.00% | Add +72.2% | 186,000 | $207K |
| Stephens Inc. | 0.00% | Reduce -1.9% | 102,000 | $113K |
| Choreo, LLC | 0.00% | New | 19,000 | $21K |
| Boussard & Gavaudan Investment Management LLP | 0.00% | New | 7,000 | $8K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 1 08/15/28)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 1 08/15/28) the manager owns.